Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer.
Times cited: 4
The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer.
Clinical Cancer Research.
Times cited: 29